Granules India Ltd., incorporated in the year 1991, is a Mid Cap company (having a market cap of Rs 7510.74 Crore) operating in Pharmaceuticals sector.
Granules India Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2021.
Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 892.68 Crore, up 4.11 % from last quarter Total Income of Rs 857.47 Crore and up 3.64 % from last year same quarter Total Income of Rs 861.34 Crore. Company reported net profit after tax of Rs 80.68 Crore in latest quarter.
Investment Rationale
Going forward, backed by passing on a substantial portion of increases to the customers along with backward integration, the company expects an improvement in gross margins. Company’s ANDA, and Dossier filings are on schedule with a total of 48 approved as of Sept’21. However since the positive triggers have already factored in, the brokerage downgrades rating from “Buy” to “Accumulate” with a target price of Rs.349 based on 12x FY23E EPS.
Promoter/FII Holdings
Promoters held 42.04 per cent stake in the company as of , while FIIs owned 21.18 per cent, DIIs 2.78 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
